ES2661737T3 - Derivados de piridina novedosos - Google Patents

Derivados de piridina novedosos Download PDF

Info

Publication number
ES2661737T3
ES2661737T3 ES14712287.3T ES14712287T ES2661737T3 ES 2661737 T3 ES2661737 T3 ES 2661737T3 ES 14712287 T ES14712287 T ES 14712287T ES 2661737 T3 ES2661737 T3 ES 2661737T3
Authority
ES
Spain
Prior art keywords
cyclopropyl
pyridin
oxadiazole
butyl
ferc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14712287.3T
Other languages
English (en)
Spanish (es)
Inventor
Olivier GAVELLE
Uwe Grether
Atsushi KIMBARA
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Didier Rombach
Tanja Schulz-Gasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2661737T3 publication Critical patent/ES2661737T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
ES14712287.3T 2013-03-26 2014-03-24 Derivados de piridina novedosos Active ES2661737T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26
EP13161176 2013-03-26
PCT/EP2014/055797 WO2014154612A1 (en) 2013-03-26 2014-03-24 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
ES2661737T3 true ES2661737T3 (es) 2018-04-03

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14712287.3T Active ES2661737T3 (es) 2013-03-26 2014-03-24 Derivados de piridina novedosos

Country Status (33)

Country Link
US (2) US10308659B2 (enExample)
EP (1) EP2978755B1 (enExample)
JP (1) JP6500010B2 (enExample)
KR (1) KR20150135458A (enExample)
CN (1) CN105121436B (enExample)
AR (1) AR095721A1 (enExample)
AU (1) AU2014243190B2 (enExample)
BR (1) BR112015024272A2 (enExample)
CA (1) CA2899168A1 (enExample)
CL (1) CL2015002835A1 (enExample)
CR (1) CR20150440A (enExample)
DK (1) DK2978755T3 (enExample)
EA (1) EA027569B1 (enExample)
ES (1) ES2661737T3 (enExample)
HR (1) HRP20180371T1 (enExample)
HU (1) HUE036934T2 (enExample)
IL (1) IL240496B (enExample)
LT (1) LT2978755T (enExample)
MA (1) MA38404B1 (enExample)
MX (1) MX365921B (enExample)
MY (1) MY174000A (enExample)
NO (1) NO2978755T3 (enExample)
PE (1) PE20151559A1 (enExample)
PH (1) PH12015501933B1 (enExample)
PL (1) PL2978755T3 (enExample)
PT (1) PT2978755T (enExample)
RS (1) RS56927B1 (enExample)
SG (1) SG11201507994QA (enExample)
SI (1) SI2978755T1 (enExample)
TW (1) TWI628174B (enExample)
UA (1) UA116239C2 (enExample)
WO (1) WO2014154612A1 (enExample)
ZA (1) ZA201505251B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708341B2 (en) * 2014-06-09 2017-07-18 Sumitomo Chemical Company, Limited Method for producing pyridine compound
PE20181203A1 (es) * 2015-12-09 2018-07-23 Hoffmann La Roche Derivados de fenilo como agonistas de receptor de cannabinoides 2
ES2847239T3 (es) * 2016-07-07 2021-08-02 Dow Agrosciences Llc Procedimientos para la preparación de 4-alcoxi-3-(acil o alquil)oxipicolinamidas
TWI886480B (zh) 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
AR112199A1 (es) 2017-06-20 2019-10-02 Hoffmann La Roche Derivados de piridina como agonistas inversos del receptor cannabinoide 2
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
EP3814328A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2020002314A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Radiolabeled cannabinoid receptor 2 ligand
SG11202009103WA (en) 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
EP3814337B1 (en) * 2018-06-27 2025-05-14 F. Hoffmann-La Roche AG Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
WO2023069721A2 (en) * 2021-10-22 2023-04-27 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法
WO2025104141A1 (en) * 2023-11-16 2025-05-22 F. Hoffmann-La Roche Ag Novel reversible fluorescent probes for cb2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
EP2049520A4 (en) 2006-08-07 2011-01-05 Ironwood Pharmaceuticals Inc indole compounds
EP2211619A1 (en) * 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
MX2014015491A (es) 2012-07-04 2015-03-06 Hoffmann La Roche Nuevos derivados de adamantilo como agonistas del receptor 2 del canabinoide.
US9512141B2 (en) 2012-12-07 2016-12-06 Hoffmann-La Roche Inc. Pyrazine derivatives as CB2 receptor agonists
CN104837831B (zh) 2012-12-07 2017-10-31 霍夫曼-拉罗奇有限公司 新的吡啶衍生物
RS56424B1 (sr) 2012-12-07 2018-01-31 Hoffmann La Roche Piridin-2-amidi korisni kao cb2-agonisti
CA2885987A1 (en) 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
PE20151539A1 (es) 2013-03-07 2015-10-28 Hoffmann La Roche Nuevos derivados de pirazol
MA39843A (fr) 2014-04-04 2017-02-08 Hoffmann La Roche Pyridine-2-amides utiles comme agonistes de cb2
SG11201608246VA (en) 2014-04-04 2016-10-28 Hoffmann La Roche 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists

Also Published As

Publication number Publication date
RS56927B1 (sr) 2018-05-31
UA116239C2 (uk) 2018-02-26
EP2978755A1 (en) 2016-02-03
JP2016516737A (ja) 2016-06-09
EA027569B1 (ru) 2017-08-31
SI2978755T1 (en) 2018-03-30
NO2978755T3 (enExample) 2018-06-02
MX365921B (es) 2019-06-20
CA2899168A1 (en) 2014-10-02
US20190248803A1 (en) 2019-08-15
PE20151559A1 (es) 2015-11-05
TWI628174B (zh) 2018-07-01
PH12015501933A1 (en) 2016-01-11
ZA201505251B (en) 2016-07-27
CR20150440A (es) 2015-10-08
IL240496A0 (en) 2015-09-24
EP2978755B1 (en) 2018-01-03
JP6500010B2 (ja) 2019-04-10
LT2978755T (lt) 2018-03-12
MA38404A1 (fr) 2017-01-31
CN105121436A (zh) 2015-12-02
PH12015501933B1 (en) 2018-12-14
TW201518287A (zh) 2015-05-16
EA201591567A1 (ru) 2016-01-29
WO2014154612A1 (en) 2014-10-02
CL2015002835A1 (es) 2016-05-20
AU2014243190A1 (en) 2015-07-30
SG11201507994QA (en) 2015-10-29
PL2978755T3 (pl) 2018-05-30
IL240496B (en) 2019-03-31
MA38404B1 (fr) 2017-09-29
CN105121436B (zh) 2018-07-27
KR20150135458A (ko) 2015-12-02
US10308659B2 (en) 2019-06-04
AR095721A1 (es) 2015-11-04
PT2978755T (pt) 2018-02-26
MY174000A (en) 2020-03-03
HUE036934T2 (hu) 2018-08-28
MX2015013629A (es) 2016-02-18
US20160016968A1 (en) 2016-01-21
BR112015024272A2 (pt) 2017-07-18
DK2978755T3 (en) 2018-03-05
HK1211938A1 (en) 2016-06-03
AU2014243190B2 (en) 2018-07-19
HRP20180371T1 (hr) 2018-04-06

Similar Documents

Publication Publication Date Title
ES2661737T3 (es) Derivados de piridina novedosos
ES2588327T3 (es) Piridin-2-amidas útiles como agonistas de CB2
TWI705966B (zh) 新穎的三唑并[4,5-d]嘧啶衍生物
ES2668690T3 (es) Derivados de piridina novedosos
ES2787855T3 (es) Derivados de fenilo como agonistas del receptor canabinoide 2
TW201336825A (zh) 雙環芳基及雜芳基化合物之鈉通道抑制劑
RU2664644C2 (ru) Новые производные тетразолона
HK1211938B (zh) 新的吡啶衍生物
BR122020008944B1 (pt) Novos derivados de triazolo [4,5-d] pirimidina
BR112016004934B1 (pt) Novos derivados de triazolo [4,5-d] pirimidina
HK1219277B (zh) 三唑并[4，5-d]嘧啶衍生物
NZ756513B2 (en) Novel triazolo[4,5-d]pyrimidine derivatives